The main findings from this study were that NNI-362 promoted proliferation and survival of adult-born neural cells associated with reversal of cognitive deficits, without toxic or off-target effects up to 6 weeks of administration, and acts allosterically and downstream of mTOR. Here, MTOR is linked to Cognitive impairment.